Keybanc Initiates Coverage On Veeva Sys with Overweight Rating, Announces Price Target of $220
Keybanc analyst Scott Schoenhaus initiates coverage on Veeva Sys (NYSE:VEEV) with a Overweight rating and announces Price Target of $220.
MKM Partners Initiates Coverage On CyberArk Software with Buy Rating, Announces Price Target of $190
MKM Partners analyst Catharine Trebnick initiates coverage on CyberArk Software (NASDAQ:CYBR) with a Buy rating and announces Price Target of $190.
MKM Partners Initiates Coverage On Fortinet with Buy Rating, Announces Price Target of $70
MKM Partners analyst Catharine Trebnick initiates coverage on Fortinet (NASDAQ:FTNT) with a Buy rating and announces Price Target of $70.
Wedbush Initiates Coverage On Vigil Neuroscience with Outperform Rating, Announces Price Target of $19
Wedbush analyst Laura Chico initiates coverage on Vigil Neuroscience (NASDAQ:VIGL) with a Outperform rating and announces Price Target of $19.
CJS Securities Initiates Coverage On AAON with Outperform Rating, Announces Price Target of $73
CJS Securities analyst Christopher Moore initiates coverage on AAON (NASDAQ:AAON) with a Outperform rating and announces Price Target of $73.
Northland Capital Markets Initiates Coverage On Transcat with Outperform Rating, Announces Price Target of $100
Northland Capital Markets analyst Ted Jackson initiates coverage on Transcat (NASDAQ:TRNS) with a Outperform rating and announces Price Target of $100.
Cantor Fitzgerald Initiates Coverage On Graphite Bio with Overweight Rating, Announces Price Target of $12
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Overweight rating and announces Price Target of $12.
Citigroup Reinstates Buy on Lucid Gr, Announces $28 Price Target
Citigroup analyst Itay Michaeli reinstates Lucid Gr (NASDAQ:LCID) with a Buy and announces $28 price target.
Janney Montgomery Scott Initiates Coverage On Capital Bancorp with Buy Rating
Janney Montgomery Scott analyst Feddie Stickland initiates coverage on Capital Bancorp (NASDAQ:CBNK) with a Buy rating.
Canaccord Genuity Initiates Coverage On KemPharm with Buy Rating, Announces Price Target of $20
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on KemPharm (NASDAQ:KMPH) with a Buy rating and announces Price Target of $20.